Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …
Investors are jumping in and out ahead of a Food and Drug Administration (FDA) decision on AcelRx’s (ACRX) opioid pain drug Dsuvia, with …
The US Food and Drug Administration (FDA) puts the needle in the arm of drug company Trevena (TRVN). The agency’s critical briefing documents …
Yesterday, the FDA approved Verastem’s (VSTM) lead product, Copiktra (duvelisib), as the first PI3K-δ/-γ inhibitor for the treatment of third-line chronic lympocytic leukemia (CLL), small …
Cowen’s Phil Nadeau takes the FDA victory for Portola in bullish stride, betting on broad adoption kicking off next year.
It’s a short and dramatic plunge for Achaogen (NASDAQ:AKAO). Today, the drug maker’s shares lost 25% of their value following the news that …
Cowen’s Chris Shibutani likes AKAO’s risk-reward set up ahead of today’s AdCom Meeting review of plazomicin.
Oppenheimer predicts TXMD to launch TX-004HR by mid-2018 with a January approval from the FDA.
Investors are racing to buy TrovaGene Inc (NASDAQ:TROV) shares after the U.S.
The next key catalyst for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Dsuvia’s Prescription Drug User Fee Act (PDUFA) on October 12, 2017 for the …
